The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 31, 2019

Filed:

Jul. 05, 2019
Applicant:

Immatics Biotechnologies Gmbh, Tuebingen, DE;

Inventors:

Annika Sonntag, Tuebingen, DE;

Toni Weinschenk, Aichwald, DE;

Andrea Mahr, Tuebingen, DE;

Oliver Schoor, Tuebingen, DE;

Jens Fritsche, Dusslingen, DE;

Harpreet Singh, Munich, DE;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/74 (2006.01); A61K 35/17 (2015.01); A61K 38/17 (2006.01); A61P 35/00 (2006.01); A61P 37/04 (2006.01); A61K 38/04 (2006.01); C07K 7/06 (2006.01); G01N 33/574 (2006.01); C12N 5/0783 (2010.01); C12Q 1/6886 (2018.01); C12N 15/115 (2010.01); C07K 16/28 (2006.01); C07K 14/725 (2006.01); A61K 39/00 (2006.01); G16B 25/00 (2019.01);
U.S. Cl.
CPC ...
C07K 14/70539 (2013.01); A61K 35/17 (2013.01); A61K 38/04 (2013.01); A61K 38/1709 (2013.01); A61K 39/0011 (2013.01); A61P 35/00 (2018.01); A61P 37/04 (2018.01); C07K 7/06 (2013.01); C07K 14/7051 (2013.01); C07K 16/2833 (2013.01); C12N 5/0636 (2013.01); C12N 5/0638 (2013.01); C12N 15/115 (2013.01); C12Q 1/6886 (2013.01); G01N 33/574 (2013.01); G01N 33/57484 (2013.01); G16B 25/00 (2019.02); A61K 2039/5158 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/55516 (2013.01); A61K 2039/55522 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/55588 (2013.01); C12N 2310/16 (2013.01); C12N 2502/11 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/70539 (2013.01);
Abstract

A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.


Find Patent Forward Citations

Loading…